These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. Author: Borràs C, Río J, Porcel J, Barrios M, Tintoré M, Montalban X. Journal: Neurology; 1999 May 12; 52(8):1636-9. PubMed ID: 10331691. Abstract: BACKGROUND: Depression has been cited as a possible side effect of interferon beta-1b (IFNbeta-1b) therapy in patients with MS. This association remains unproven because of a lack of longitudinal studies. OBJECTIVE: To determine the changes in emotional state in relapsing-remitting (RR) MS patients during the first 2 years of treatment with IFNbeta-1b. METHODS: Emotional state was evaluated in a sample of 90 patients at the onset of IFNbeta-1b treatment during an inclusion period of 2.5 years. Seventy-five patients were evaluated at their 12th month of treatment and 56 patients at their 24th month. We assessed their emotional state with the following psychological tests: Hamilton Depression Rating Scale, Beck Depression Inventory, and State-Trait Anxiety Inventory. RESULTS: We found significant improvement in emotional state after the first and second years of treatment. CONCLUSIONS: Our findings show that IFNbeta-1b does not increase depression or anxiety in RR MS patients during the first and second years of IFNbeta-1b treatment. In fact, slight but significant improvement in depression and anxiety symptoms was observed during this period.[Abstract] [Full Text] [Related] [New Search]